---
document_datetime: 2024-08-02 11:12:56
document_pages: 32
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/evicel-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: evicel-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 14.4791852
conversion_datetime: 2025-12-28 03:44:26.109827
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Evicel

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                          | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| PSUSA/10297 /202306  | Periodic Safety Update EU Single assessment - human fibrinogen / human thrombin                                                                                                                                                                | 11/01/2024                                  | n/a                                         |                                  | PRAC Recommendation - maintenance |
| IAIN/0103            | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 18/07/2023                                  | n/a                                         |                                  |                                   |

Medicinal product no longer authorised

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IAIN/0102   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                     | 05/06/2023        | n/a                                                                                                                                                                                                                                                                                       |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0099     | Please refer to the Recommendations section above C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                | 16/03/2023        | 01/03/2024 SmPC and PL Following the submission of the paediatric study BIOS-13- 006, section 4.8 and 5.1 of the SmPC is up-dated to add pseudomeningocele to the list of ADRs with frequency uncommon and to update efficacy and safety information on paediatric population. authorised |
| IAIN/0101/G | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP Medicinal product | 06/02/2023 n/a no | longer                                                                                                                                                                                                                                                                                    |
| IAIN/0100   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes                                                                                                                                                                                                                                                                                                                                                            | 12/12/2022        | n/a                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|             | do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |                |                                                                            |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------|----------------------------------------------------------------------------|
| IAIN/0098   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                              | 31/10/2022 | n/a authorised |                                                                            |
| IAIN/0097/G | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - when changes                                                       | 18/07/2022 | n/a no longer  | Inclusion of an updated/amended PMF do not affect the properties of the FP |
| IAIN/0096/G | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes Medicinal product | 04/07/2022 | n/a            |                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|             | do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                       |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| IAIN/0095   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                     | 23/06/2022 n/a        |
| IAIN/0094   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                     | 04/10/2021 n/a longer |
| IAIN/0093   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                     | 02/09/2021 n/a no     |
| IAIN/0092/G | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP Medicinal product | 05/08/2021 n/a        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                    |                          |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| IAIN/0091 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                    | 05/08/2021 n/a           |
| IAIN/0090 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                    | 02/08/2021 n/a no longer |
| IA/0089/G | This was an application for a group of variations. B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier product | 15/07/2021 n/a           |
| IAIN/0088 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP Medicinal                                                                          | 01/02/2021 n/a           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| PSUSA/10297 /202006   | Periodic Safety Update EU Single assessment - human fibrinogen / human thrombin                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 14/01/2021   | n/a        | PRAC            |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|
| IAIN/0087             | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                                                           | 12/01/2021   | n/a        | authorised      |
| IAIN/0086/G           | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP product | 10/11/2020   | n/a no     | longer          |
| IA/0085               | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 28/10/2020   | 16/07/2021 | Annex II and PL |
| IAIN/0083             | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP Medicinal                                                                                                                                                                                                                                                                                                 | 29/05/2020   | n/a        |                 |

<div style=\"page-break-after: always\"></div>

| IA/0082/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.e - Change in test procedure for the finished product - Update of the test procedure to comply with the updated general monograph in the Ph. Eur.   | 29/05/2020   | n/a           | authorised                        |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|-----------------------------------|
| IAIN/0081           | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                             | 08/05/2020   | n/a longer    |                                   |
| II/0078             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                          | 02/04/2020   | 16/07/2021 no | SmPC and PL                       |
| IAIN/0080           | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP Medicinal product                                                                                                                           | 16/01/2020   | n/a           |                                   |
| PSUSA/10297 /201906 | Periodic Safety Update EU Single assessment - human fibrinogen / human thrombin                                                                                                                                                                                                                                                                                                            | 16/01/2020   | n/a           | PRAC Recommendation - maintenance |
| IAIN/0079           | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier                                                                                                                                                                                                                                                                                        | 27/11/2019   | n/a           |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                             |            |                |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------|
| IB/0075   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                           | 22/08/2019 | n/a authorised |
| IAIN/0076 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP         | 15/08/2019 | n/a longer     |
| IAIN/0074 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP product | 25/07/2019 | n/a no         |
| IB/0072   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate Medicinal                                 | 17/07/2019 | n/a            |
| IB/0073   | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                             | 03/07/2019 | n/a            |

<div style=\"page-break-after: always\"></div>

| II/0067             | B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS                                                                              | 02/05/2019   | n/a           |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|-----------------------------------|
| IAIN/0070           | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP           | 10/04/2019   | n/a           | authorised                        |
| IAIN/0069           | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP           | 02/04/2019   | n/a no longer |                                   |
| IAIN/0068           | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP           | 01/04/2019   | n/a product   |                                   |
| IAIN/0066           | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP Medicinal | 01/03/2019   | n/a           |                                   |
| PSUSA/10297 /201806 | Periodic Safety Update EU Single assessment - human fibrinogen / human thrombin                                                                                                                                                                          | 17/01/2019   | n/a           | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| II/0063             | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   | 29/11/2018   | n/a                                                   | authorised                                                                                                                                                                                                                                                           |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0062/G           | This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                     | 16/11/2018   | n/a                                                   |                                                                                                                                                                                                                                                                      |
| R/0054              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                          | 28/06/2018   | 23/08/2018 SmPC, Annex II, Labelling and PL no longer | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Evicel in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| II/0059             | B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS product                                                                                                              | 26/07/2018   | n/a                                                   |                                                                                                                                                                                                                                                                      |
| PSUSA/10297 /201712 | Periodic Safety Update EU Single assessment - human fibrinogen / human thrombin                                                                                                                                                                                                                  | 12/07/2018   | n/a                                                   | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Evicel in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IAIN/0061           | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier Medicinal                                                                                                                                                                                    | 06/06/2018   | n/a                                                   |                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|             | of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                                                |            |                          |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------------------------|
| IAIN/0060/G | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes | 06/06/2018 | n/a longer               |
| IB/0058/G   | This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation B.II.z - Quality change - Finished product - Other                                                                                                                                                                                                                                                                                                                                        | 15/05/2018 | variation n/a product no |
| IAIN/0057   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP Medicinal                                                                                                                                                                                                                                                  | 15/03/2018 | n/a                      |
| II/0053     | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The                                                                                                                                                                                                                                                                                                                                                                                                  | 08/02/2018 | n/a                      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|             | change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |               |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|
| IAIN/0055/G | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or Medicinal product | 15/01/2018 | n/a no longer |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                              |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|
| PSUSA/10297 /201706 | Periodic Safety Update EU Single assessment - human fibrinogen / human thrombin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 11/01/2018 n/a               |
| N/0052              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 11/09/2017 23/08/2018 longer |
| IAIN/0051/G         | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Medicinal product | 18/08/2017 n/a no            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - product   | no longer authorised   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|
| IAIN/0049 | Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP 18/08/2017 Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | n/a                    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0048             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                       | 16/08/2017         | n/a           | authorised                        |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------|-----------------------------------|
| PSUSA/10297 /201612 | Periodic Safety Update EU Single assessment - human fibrinogen / human thrombin                                                                                                                                                                                                                                                                                                                                                    | 06/07/2017         | n/a           | PRAC Recommendation - maintenance |
| IA/0047/G           | This was an application for a group of variations. B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) | 28/04/2017         | n/a no longer |                                   |
| IB/0045             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                   | 25/04/2017 product | n/a           |                                   |
| IA/0046             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                      | 07/04/2017         | n/a           |                                   |
| PSUSA/10297 /201606 | Periodic Safety Update EU Single assessment - human fibrinogen / human thrombin Medicinal                                                                                                                                                                                                                                                                                                                                          | 12/01/2017         | n/a           | PRAC Recommendation - maintenance |
| IB/0043/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                 | 22/12/2016         | n/a           |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | B.II.z - Quality change - Finished product - Other variation B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                                                                                                                                                                        |            |            |                                                                                         |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------------------------------------------------------------------------|
| IA/0042/G           | This was an application for a group of variations. B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test | 19/10/2016 | n/a longer | authorised                                                                              |
| II/0039             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                    | 15/09/2016 | n/a no     | Update of the Risk Management Plan (Version 14). The variation is not affecting the PI. |
| IB/0041             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data product                                                                                                                                                                                                                                                                                                   | 05/09/2016 | n/a        |                                                                                         |
| PSUSA/10297 /201512 | Periodic Safety Update EU Single assessment - human fibrinogen / human thrombin                                                                                                                                                                                                                                                                                                                                                                                                  | 07/07/2016 | n/a        | PRAC Recommendation - maintenance                                                       |
| IA/0038             | B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant Medicinal                                                                                                                                                                                                                                                                                                                   | 22/04/2016 | n/a        |                                                                                         |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                                                                                                                                                                                                                                                  |            |               |                                              |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|----------------------------------------------|
| PSUSA/10297 /201506 | Periodic Safety Update EU Single assessment - human fibrinogen / human thrombin                                                                                                                                                                                                                                                                                                                                                                                                   | 14/01/2016 | n/a           | PRAC Recommendation - maintenance authorised |
| IB/0036/G           | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of | 03/12/2015 | n/a no longer |                                              |
| II/0032             | an obsolete parameter) Update of section 4.8 of the SmPC in order to update the frequencies from common to uncommon of ADRs regarding vascular surgery already reported in the Product Information. A minor change is introduced in section 4.2 of the SmPC. The Package Leaflet and the RMP (adopted version: 13.0) are updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data Medicinal product | 19/11/2015 | 24/10/2016    | SmPC and PL                                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| II/0029/G   | This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a   | 22/10/2015         | 24/10/2016 longer   | SmPC, Annex II and PL authorised   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------------|------------------------------------|
| IB/0035/G   | applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or Medicinal                                                                                           | 05/10/2015 product | n/a                 |                                    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                    | starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate   |            |               | authorised                        |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|-----------------------------------|
| IB/0033/G          | This was an application for a group of variations. B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation                                                                                                                           | 10/09/2015 | n/a no longer |                                   |
| PSUSA/1627/ 201412 | Periodic Safety Update EU Single assessment - human fibrinogen, human thrombin (all pharmaceutical dose forms except for sealant matrix) product                                                                                                                                                                                                                             | 09/07/2015 | n/a           | PRAC Recommendation - maintenance |
| PSUSA/1627/ 201410 | Periodic Safety Update EU Single assessment - human fibrinogen, human thrombin (all pharmaceutical dose forms except for sealant matrix)                                                                                                                                                                                                                                     | 07/05/2015 | n/a           | PRAC Recommendation - maintenance |
| IB/0028/G          | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) Medicinal                                                                                                                | 18/12/2014 | n/a           |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | B.I.b.1.i - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Where there is no monograph in the European/National Ph. for the AS, a change in specification from in-house to a non- official/third country Ph. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.e.2.d - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition or replacement of a specification parameter as a result of a safety or quality issue B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.I.b.2.a - Change in test procedure for AS or product   | no         | longer                | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0026 | This variation concerned an update of section 6.6 of the SmPC with instructions regarding the use of EVICEL Fibrin Sealant applicator tips. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to update the ATC code in section 5.1 of the SmPC as well as to make minor editorial changes to the SmPC, Annex II and the Package Leaflet. 23/10/2014 Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 27/01/2015 | SmPC, Annex II and PL | As part of this application, the MAH proposed to revise the EVICEL product information with instructions regarding the use of additional EVICEL Fibrin Sealant accessory tips; a 4 cm Control Tip, a 45 cm tip, and an Airless Spray Accessory. Detailed instructions for use of these accessory tips have not been included in the Product Information as it should be provided together with the devices. However, for the proposed 45 cm flexible tip, the CHMP was of the view that distance and pressure recommendations should be |

<div style=\"page-break-after: always\"></div>

PSUV/0027

II/0025/G

C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required

Periodic Safety Update

This was an application for a group of variations.

Changes to the quality documentation

A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal

08/05/2014

included in the Product Information. Under the prerequisite of compliance with distance requirements, CHMP considered the 45 cm flexible accessory tip acceptable. It can be used in both open and laparoscopic procedures, but is especially designed for the use in laparoscopic procedures. For open surgery a pressure range of 1.4 - 1.7 bar is proposed, however, the range appears unnecessarily high for laparoscopic procedures. Following life-threatening events of air/gas embolism the spray pressure used in laparoscopic procedures was limited to a maximum of 1.4 bar (Article 20 referral). No clinically relevant advantage could be demonstrated for 1.7 bar over 1.4 bar for the small distances used within laparoscopic procedures. On the other hand a pressure of 1.0 bar cannot produce a sufficient mixing of the two sealant components. It is therefore recommended to use the 45 cm flexible tip in laparoscopic procedures at a spray gas pressure of 1.4 bar. The product information has been revised accordingly.

PRAC Recommendation - maintenance n/a 23/01/2014 27/01/2015 SmPC, Labelling and PL Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                        |                    |               |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0023 | Introduction of additional batch testing laboratory for release in EU. B.II.b.2.b.3 - Change to batch release arrangements and quality control testing of the FP - Including batch control/testing for a biol/immunol product and one of the test methods is a biol/immunol/immunochemical method                                                                                                                     | 21/11/2013         | n/a           | longer                           | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| R/0022  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                               | 24/10/2013         | 20/11/2013 no | SmPC, Annex II, Labelling and PL | The benefit - risk balance of Evicel in the approved indications of supportive treatment in surgery where standard surgical techniques are insufficient, for improvement of haemostasis and suture support for haemostasis in vascular surgery and for suture line sealing in dura mater closure, remains positive. A further update of the Risk Management system is requested by the CHMP by 16 December 2013 as the same time with the Periodic Safety Update Report to ensure ongoing implementation of all risk minimisation measures agreed to eliminate the risk of air embolism. |
| II/0021 | Extension of indication to include: use for 'suture line sealing in dura mater closure' for Evicel. As a consequence, update of sections 4.1, 4.2, 4.3, 4.4, 4.8, and 5.1 of the SmPC in order to relevant posology, contra-indications, warnings, safety information. The Package Leaflet is updated in accordance. Furthermore, the PI is being brought in line with the latest QRD template version 9.0. Medicinal | 27/06/2013 product | 26/07/2013    | SmPC, Annex II, Labelling and PL | Please refer to the Scientific Discussion Evicel-H-C-0898-II- 21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|             | Minor editorial amendments were also implemented in the PI. The requested variation proposed amendments to the SmPC, Annex II, Labelling and Package Leaflet. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                                             |                    |               |                              | authorised                                                        |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------|------------------------------|-------------------------------------------------------------------|
| A20/0018    | Pursuant to Article 20 of Regulation (EC) No. 726/2004, the European Commission requested the CHMP to re-evaluate the benefit-risk balance of the use of Evicel with a spray device in light of newly available data on the risk of life-threatening gas embolism following spray application of Evicel, and to give its opinion on measures necessary to ensure the safe and effective use of Evicel, and on whether the marketing authorisation for this product should be maintained, varied, suspended or withdrawn. | 15/11/2012         | 13/02/2013 no | SmPC, Annex II and PL longer | Please refer to the assessment report: EMEA/H/C/000898/A-20/0018. |
| II/0020     | Change in test procedure B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Change (replacement) to a biological/immunological/ immunochemical test method or a method using a biological reagent for a biological AS Medicinal                                                                                                                                                                                                                                                     | 13/12/2012 product | n/a           |                              |                                                                   |
| IAIN/0019/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 20/07/2012         | n/a           |                              |                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV   | product    | no         | longer                    | authorised                                                                                                                                                                                                                                                                                                                 |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0016 | B.I.c.1.c - Change in immediate packaging of the AS - Liquid ASs (non sterile)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 17/07/2012 | n/a        |                           |                                                                                                                                                                                                                                                                                                                            |
| IB/0014 | C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 16/01/2012 | 26/07/2012 | SmPC                      | Following review of PSUR 5 EMA requested to add details concerning pressure and distance for spray applications to section 6.6 of the SPC 'Instructions for use, handling and disposal' under sub header 'Spray application'. These parameters currently appear in section 4.4 'Special warnings and precautions for use'. |
| IA/0013 | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 07/10/2011 | n/a        | SmPC, Annex II, Labelling |                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |               | and PL                 |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|------------------------|
| IB/0011   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                           | 08/07/2011 | n/a           | authorised             |
| IB/0012   | B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product                                                                                                                                                                                                                                                                                                                                                                                   | 06/07/2011 | n/a           | SmPC, Labelling and PL |
| II/0009/G | This was an application for a group of variations. Changes to the active substance and finished product manufacture. B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change requires assessment of the comparability of a biological/immunological medicinal product product | 17/02/2011 | 08/03/2011 no | longer                 |
| II/0007/G | This was an application for a group of variations. 1. Change in active substance control method. 2. Change in active substance specification. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Change (replacement) to a biological/immunological/ Medicinal                                                                                                                                                                                                        | 20/01/2011 | 27/01/2011    |                        |

<div style=\"page-break-after: always\"></div>

|           | immunochemical test method or a method using a biological reagent for a biological AS B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS                                                                                                                                                                                                                                                                                                     |               |                                  | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0010/G | This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of                                                                                                                            | 17/01/2011 no | n/a Annex II longer              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0006   | Update of sections 4.4 and 6.6 of the Summary of Product Characteristics with regards to the risk of air embolism associated with the spray application of Evicel following the assessment of the 1st and 2nd PSUR. The Package Leaflet has been udpated accordingly. Furthermore, Annex II has been updated accordingly in order to include the latest version number of the RMP (version RMP-002-01). C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article Medicinal product | 24/06/2010    | 06/08/2010 SmPC, Annex II and PL | In the 1st Evicel PSUR (PSU 010), two cases of air embolism have been reported following the application of Quixil (another fibrin sealant) using the spray application device with pressurised gas or air in conjunction with a pressure regulator. In the 2nd Evicel PSUR (PSU 011), three cases of air embolism have been reported following the application of Evicel (one case) or Quixil (two cases) using the spray application device. Following the assessment of the two PSURs, the MAH was requested by the CHMP to submit a type II variation to update sections 4.4 and 6.6 of the Summary of Product Characteristics, the Risk Management Plan and to come up with a proposal of |

<div style=\"page-break-after: always\"></div>

|         | 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH   |                    |                                             | Direct Healthcare Professional Communication. The MAH has hereby submitted a type II variation. The CHMP considered this type II variation acceptable and agreed on amendments to be introduced in the Summary of Product Characteristics and the Package Leaflet, on the revised Risk Management Plan and the proposed Direct Healthcare Professional Communication. authorised   |
|---------|--------------------------------------------------------------------------------------------------------|--------------------|---------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0004 | Change of shelf life of final product. Quality changes                                                 | 18/02/2010         | 30/03/2010 SmPC, Labelling and PL           | Change of shelf life of final product.                                                                                                                                                                                                                                                                                                                                             |
| II/0003 | Change to Thrombin drug substance manufacture. Quality changes                                         | 17/12/2009         | 09/02/2010 longer                           | Change to Thrombin drug substance manufacture.                                                                                                                                                                                                                                                                                                                                     |
| II/0005 | Changes to QPPV                                                                                        | 19/11/2009         | 15/12/2009 Annex II no                      | The CHMP considers that the change of QPPV as described by the MAH fulfils the requirements and is considered acceptable. Consequently, Annex II has been updated with the new version number of the agreed DDPS (version 11- 01-05).                                                                                                                                              |
| II/0002 | Change to active substance manufacture of Thrombin. Quality changes                                    | 24/09/2009 product | 30/09/2009                                  | Change to active substance manufacture of Thrombin.                                                                                                                                                                                                                                                                                                                                |
| II/0001 | Update of Summary of Product Characteristics, Labelling and Package Leaflet Medicinal                  | 19/03/2009         | 23/04/2009 SmPC, Annex II, Labelling and PL | Update of the instructions for use in section 6.6 of the SPC and in the Package Leaflet further to the results of an animal comparability study evaluating the functional performance of the device in laparoscopic surgery using the 35cm tip. In addition, the date of first authorisation and MA numbers were added in the PI where appropriate. The MAH                        |

<div style=\"page-break-after: always\"></div>

| also took the opportunity to make minor editorial changes.   |
|--------------------------------------------------------------|

<!-- image -->